Jenny Kim

Jenny Kim possesses extensive experience in quality control and product development within the biopharmaceutical sector. Currently serving as Director, Product Quality Lead at Allogene Therapeutics since January 2019, Jenny has held multiple leadership roles focused on QC Cell and Molecular Biology. Prior to this, tenure at Bayer from September 2012 to January 2019 included positions as Quality Control Manager and Sr. Specialist, where expertise in cGMP and regulatory guidelines played a critical role in impurity analysis and method development. Earlier research at UCSF and Texas A&M University Health Science Center emphasized infectious disease and bacterial pathogenesis, contributing to a strong academic foundation that includes a PhD and postdoctoral training from UCSF.